Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 6
2006 2
2007 1
2008 2
2009 5
2010 2
2011 3
2012 2
2013 6
2014 2
2015 3
2016 1
2017 2
2018 7
2019 6
2020 9
2021 11
2022 9
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Tienhoven G, van Eijck CHJ; Dutch Pancreatic Cancer Group. Versteijne E, et al. Among authors: eskens falm. J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27. J Clin Oncol. 2022. PMID: 35084987 Clinical Trial.
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, Eskens FALM, Festen S, de Groot JWB, Groot Koerkamp B, de Hingh IH, Homs MYV, van Hooft JE, Kerver ED, Luelmo SAC, Neelis KJ, Nuyttens J, Paardekooper GMRM, Patijn GA, van der Sangen MJC, de Vos-Geelen J, Wilmink JW, Zwinderman AH, Punt CJ, van Eijck CH, van Tienhoven G; Dutch Pancreatic Cancer Group. Versteijne E, et al. Among authors: eskens falm. J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27. J Clin Oncol. 2020. PMID: 32105518 Free PMC article. Clinical Trial.
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schöffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S. Jones RL, et al. Among authors: eskens falm. Eur J Cancer. 2021 Mar;145:132-142. doi: 10.1016/j.ejca.2020.12.008. Epub 2021 Jan 16. Eur J Cancer. 2021. PMID: 33465704 Free PMC article. Clinical Trial.
Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Dijkstra KK, van den Berg JG, Weeber F, van de Haar J, Velds A, Kaing S, Peters DDGC, Eskens FALM, de Groot DA, Tesselaar MET, Voest EE. Dijkstra KK, et al. Among authors: eskens falm. Front Endocrinol (Lausanne). 2021 Mar 11;12:627819. doi: 10.3389/fendo.2021.627819. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33776923 Free PMC article. Clinical Trial.
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. Hamid O, et al. Among authors: eskens falm. J Immunother Cancer. 2022 Oct;10(10):e005471. doi: 10.1136/jitc-2022-005471. J Immunother Cancer. 2022. PMID: 36302562 Free PMC article. Clinical Trial.
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.
Zeverijn LJ, van Waalwijk van Doorn-Khosrovani SB, van Roy AAMGP, Timmers L, Ly Tran TH, de Boer JE, de Wit GF, Geurts BS, Gelderblom H, Verheul HMW, Blijlevens N, Wymenga ANM, Eskens FALM, Smit EF, Bloemendal HJ, Voest EE. Zeverijn LJ, et al. Among authors: eskens falm. Lancet Oncol. 2022 Feb;23(2):198-201. doi: 10.1016/S1470-2045(21)00707-5. Lancet Oncol. 2022. PMID: 35114116 No abstract available.
A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours.
Robbrecht DGJ, Lopez J, Calvo E, He X, Hiroshi H, Soni N, Cook N, Dowlati A, Fasolo A, Moreno V, Eskens FALM, de Bono JS. Robbrecht DGJ, et al. Among authors: eskens falm. Br J Cancer. 2021 Jan;124(2):391-398. doi: 10.1038/s41416-020-01100-3. Epub 2020 Oct 6. Br J Cancer. 2021. PMID: 33020594 Free PMC article. Clinical Trial.
73 results